LTS LOHMANN Therapie-Systeme AG

LTS LOHMANN Therapie-Systeme has inked a strategic partnership with Grand River Aseptic Manufacturing, focused on the sterile fill finish for containers used in LTS’ Sorrel wearable injector devices. This collaboration offers pharmaceutical companies a comprehensive solution for both the development and manufacturing of wearable injectors specifically designed for the delivery of biologics. This collaboration ensures an integrated approach from concept to completion, facilitating faster market access and streamlined production processes. Sorrel is a next-generation on-body delivery system for large-volume and/or viscous drug formulations designed for patient convenience and pharmaceutical efficiency. Its patented technology supports multiple drugs and indications for smart, reliable at-home delivery. Intuitive for users, Sorrel™ helps pharmaceutical partners reduce development risks like safety, efficacy, cost, and time-to-market. Grand River Aseptic Manufacturing (GRAM) is an aseptic filling and finishing expert, particularly for injectable biologics. Their capabilities span sterile production, regulatory guidance, and product development support with scalable manufacturing solutions tailored to diverse pharmaceutical needs. GRAM is adept at handling the complex requirements of sterile fill finish for specialized containers such as cartridges and wearable injectors, leveraging its extensive expertise to benefit pharmaceutical clients. Pharmaceutical companies can benefit from a strategic collaboration between LTS and GRAM, offering an end-to-end solution for delivering advanced on-body delivery systems with pre-loaded and pre-filled containers. This collaboration streamlines product development, commercialization, and delivery of Sorrel™ Devices by combining LTS’s innovative device solutions with GRAM’s specialized aseptic manufacturing capabilities. “We see a very synergistic alliance between LTS and GRAM, creating a mutually beneficial collaboration that particularly supports our customers’ journey from molecule to market,” said Dr. Andrei Yosef, President and General Manager of LTS Device Technologies. “The combination of GRAM’s fill-finish expertise with LTS’s proprietary Sorrel drug delivery technology will deliver a streamlined solution that meets the unique needs of our customers,” Dr. Andrei Yosef added. “We are excited to embark on this collaboration with LTS, as on-body wearable injectors are crucial for advancing patient care. This collaboration leverages our dedicated efforts, combining GRAM’s specialized aseptic manufacturing capabilities with LTS’s innovative device technology. Together, we are not only advancing the technology but also enhancing patient care by making sophisticated treatments more accessible and easier to use,” said Dave Powell, Vice President of Business Development at Grand River Aseptic Manufacturing (GRAM).

LTS LOHMANN Therapie-Systeme has inked a strategic partnership with Grand River Aseptic Manufacturing, focused on the sterile fill finish for containers used in LTS’ Sorrel wearable injector devices. This collaboration offers pharmaceutical companies a comprehensive solution for both the development and manufacturing of wearable injectors specifically designed for the delivery of biologics. This collaboration ensures an integrated approach from concept to completion, facilitating faster market access and streamlined production processes. Sorrel is a next-generation on-body delivery system for large-volume and/or viscous drug formulations designed for patient convenience and pharmaceutical efficiency. Its patented technology supports multiple drugs and indications for smart, reliable at-home delivery. Intuitive for users, Sorrel™ helps pharmaceutical partners reduce development risks like safety, efficacy, cost, and time-to-market. Grand River Aseptic Manufacturing (GRAM) is an aseptic filling and finishing expert, particularly for injectable biologics. Their capabilities span sterile production, regulatory guidance, and product development support with scalable manufacturing solutions tailored to diverse pharmaceutical needs. GRAM is adept at handling the complex requirements of sterile fill finish for specialized containers such as cartridges and wearable injectors, leveraging its extensive expertise to benefit pharmaceutical clients. Pharmaceutical companies can benefit from a strategic collaboration between LTS and GRAM, offering an end-to-end solution for delivering advanced on-body delivery systems with pre-loaded and pre-filled containers. This collaboration streamlines product development, commercialization, and delivery of Sorrel™ Devices by combining LTS’s innovative device solutions with GRAM’s specialized aseptic manufacturing capabilities. “We see a very synergistic alliance between LTS and GRAM, creating a mutually beneficial collaboration that particularly supports our customers’ journey from molecule to market,” said Dr. Andrei Yosef, President and General Manager of LTS Device Technologies. “The combination of GRAM’s fill-finish expertise with LTS’s proprietary Sorrel drug delivery technology will deliver a streamlined solution that meets the unique needs of our customers,” Dr. Andrei Yosef added. “We are excited to embark on this collaboration with LTS, as on-body wearable injectors are crucial for advancing patient care. This collaboration leverages our dedicated efforts, combining GRAM’s specialized aseptic manufacturing capabilities with LTS’s innovative device technology. Together, we are not only advancing the technology but also enhancing patient care by making sophisticated treatments more accessible and easier to use,” said Dave Powell, Vice President of Business Development at Grand River Aseptic Manufacturing (GRAM).

LTS LOHMANN Therapie-Systeme AG (LTS), a pharmaceutical technology company, has made a stride in the realm of biologics with the launch of its Sorrel™ wearable drug delivery platform in collaboration with Coherus BioSciences, Inc. (Coherus). The platform debuts alongside Coherus' UDENYCA® on-body injector (OBI), a solution for administering pegfilgrastim-cbqv, a biosimilar pegfilgrastim utilized post-chemotherapy to mitigate infection risks. UDENYCA® OBI, endorsed by the US Food and Drug Administration (FDA) in December 2024, symbolises a leap forward in performance, quality, reliability, and patient convenience within the realm of wearable injection devices. This innovative delivery system, born from the collaboration between Coherus and LTS, epitomizes a concerted effort to enhance patient care by providing a user-friendly, at-home administration option. Bas van Buijtenen, CEO of LTS, expressed his satisfaction with the market entry into biologics, citing, "This launch completes the market entry of LTS into Biologics, bringing the ease of administration that LTS's solutions are known for to new class of therapies. Our capacity is ready to scale up, providing access to this advantageous solution to all patients swiftly." Dr. Andrei Yosef, President and General Manager of LTS Device Technologies, underscored the significance of FDA approval and subsequent launch as a testament to the Sorrel™ platform's capabilities. "Approval and launch will accelerate our other partnered programs running on the same platform, as well as programs with partners looking to obtain market access in the future," Yosef said. The launch of UDENYCA® OBI marks a pivotal moment for both LTS and Coherus, signifying a successful collaboration aimed at revolutionizing drug delivery in the biologics space.